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Abstract
Background: The molecular and biological mechanisms by which many antidepressants function are based on the
monoamine depletion hypothesis. However, the entire cascade of mechanisms responsible for the therapeutic
effect of antidepressants has not yet been elucidated.
Results: We used a genome-wide microarray system containing 30,000 clones to evaluate total RNA that had been
isolated from the brains of treated rats to identify the genes involved in the therapeutic mechanisms of various
antidepressants, a tricyclic antidepressant (imipramine). a selective serotonin reuptake inhibitor (fluoxetine), a
monoamine oxidase inhibitor (phenelzine) and psychoactive herbal extracts of Nelumbinis Semen (NS). To confirm
the differential expression of the identified genes, we analyzed the amount of mRNA that was isolated from the
hippocampus of rats that had been treated with antidepressants by real-time RT-PCR using primers specific for
selected genes of interest. These data demonstrate that antidepressants interfere with the expression of a large
array of genes involved in signaling, survival and protein metabolism, suggesting that the therapeutic effect of
these antidepressants is very complex. Surprisingly, unlike other antidepressants, we found that the standardized
herbal medicine, Nelumbinis Semen, is free of factors that can induce neurodegenerative diseases such as caspase
8, a-synuclein, and amyloid precursor protein. In addition, the production of the inflammatory cytokine, IFNg, was
significantly decreased in rat hippocampus in response to treatment with antidepressants, while the inhibitory
cytokine, TGFb, was significantly enhanced.
Conclusions: These results suggest that antidepressants function by regulating neurotransmission as well as
suppressing immunoreactivity in the central nervous system.
Background
Most antidepressants enhance serotonergic or noradre-
nergic neurotransmission by inhibiting monoamine
oxidase or by binding to neurotransmitter transporters,
thereby inhibiting neurotransmitter re-uptake. Although
antidepressants are widely used to treat depression, they
often produce various adverse side effects such as sexual
dysfunction, anxiety, blurred vision, headache, sleep dis-
ruption, constipation, nausea, sedation, and weight gain
[1,2]. There are many classes of antidepressants, includ-
ing monoamine oxidase inhibitors (MAOIs), tricyclic
antidepressants (TCAs), tetracyclic antidepressants
(TeCAs), selective serotonin reuptake inhibitors (SSRIs),
and serotonin-norepinephrine reuptake inhibitors
(SNRIs). Fluoxetine has been shown to be effective for
the treatment of depression in long-term controlled
trials that also revealed it alleviated anxiety and
improved sleep. The tricyclic antidepressant, imipra-
mine, is a dibenzazepine that is primarily used for the
treatment of clinical depression and enuresis. Specifi-
cally, imipramine is a tertiary amine that inhibits the
reuptake of serotonin more effectively than most sec-
ondary amine tricyclic antidepressants because it blocks
reuptake of the neurotransmitters serotonin and norepi-
nephrine almost equally. Imipramine also exerts activity
at the δ-opiate receptors and the dopamine receptors [3].
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tor (MAOI) that is used as an antidepressant. Phenelzine
is a derivative of hydrazine, which is a phenylethylamine-
like moiety that is similar to normal substrates of
MAO [4,5]. When MAO attempts to oxidize phenelzine,
t h eh y d r a z i n e - m o i e t yb i n d sc o v a l e n t l yt ot h ee n z y m e ,
thereby irreversibly inactivating it. This may contribute to
its anxiolytic properties and superior efficacy when treat-
ing severe anxiety [6]. Tetracyclic antidepressants (TeCAs)
are named after their chemical structure, which contains
four rings of atoms. The representative TeCAs, amoxapine
and maprotiline, are closely related to tricyclic antidepres-
sants, which contain three rings of atoms. Serotonin-
norepinephrine reuptake inhibitors (SNRIs) are used in
the treatment of major depression and mood disorders [7].
SNRIs play a role in the inhibition of serotonin and nore-
pinephrine reuptake, which results in an increase in the
concentrations of serotonin and norepinephrine and thus
an increase in neurotransmission. Most SNRIs, including
venlafaxine, desvenlafaxine, and duloxetine, are several
fold more selective for serotonin over norepinephrine.
SNRIs are sometimes used to treat anxiety disorders, such
as obsessive-compulsive disorder (OCD), attention deficit
hyperactivity disorder (ADHD), and chronic neuropathic
pain [8]. Nelumbinis Semen (NS) is a traditional medicine
that has been used for hundreds of years in East-Asia to
treat insomnia, anxiety and women’s post-menstrual-
pause depression [9]. In previous studies, this herbal medi-
cine was found to exert an antidepressant-like effect in
rats when examined by the Porsolt forced swim test. The
results of that study also suggested that Nelumbinis Semen
could increase local cholinergic and dopaminergic or nore-
phinergic neurotransmission via activation of cAMP for-
mation in the hippocampus and pre-frontal cortex [10,11].
The present study was conducted to identify relevant
genes that could be involved in the action of four types
of antidepressants (fluoxetine, imipramine, phenelzine
and Nelumbinis Semen). To identify changes in the gene
profile after treatment with these four drugs for various
lengths of time, we conducted the microarray test for
one (acute), three and seven (chronic) days. We also
investigated whether genes involved in the acute condi-
tion could be replicated in chronic condition or not.
T h er e s u l t so ft h i ss t u d yw i l ll i k e l yi n c r e a s eo u ru n d e r -
standing of the mechanisms by which drug actions
occur and provide insight into the way in which cells
respond to and adapt to drug exposure.
Results
DNA microarray analysis of RNA isolated from pretreated
rat hippocampus
We used a genome-wide microarray analysis to examine
changes in the gene expression profile of rats after treat-
ment with antidepressants or Nelumbinis Semen for one,
three and seven days. Of the 30,000 genes evaluated in
the present study, the expression of 35, 49, 37 and 44
genes decreased, whereas that of 21, 20, 35 and 27
genes were over-expressed in response to treatment
with imipramine, fluoxetine, phenelzine and Nelumbinis
Semen, respectively (Figure 1). The genes that were sig-
nificantly repressed and over-expressed in response to
treatment are shown in Table 1 and 2.
Treatment with Nelumbinis Semen resulted in signifi-
cant up-regulation of four (Glial cell line derived neuro-
trophic factor superfamily receptor alpha 2, Macrophage
expressed gene 1, Activity-dependent neuroprotective
protein, Fyn proto-oncogene), six (Nerve growth factor
beta, Type 1 tumor necrosis factor receptor regulator,
Leptin receptor, Adrenomedullin, Syntaxin 1A, Epsin 1),
and five (Transforming growth factor, beta 2, Growth
differentiation factor 15, Adrenomedullin receptor,
Regucalcin, Syntaxin 11) genes and significant down-
regulation of three (Immunoglobulin superfamily mem-
ber 6, Tumor necrosis factor alpha induced protein 6,
Leukocyte cell derived chemotaxin 1), four (Serum amy-
loid A 4, Angiopoietin 1, Apoptosis facilitator Bcl-2-like
protein 14, Interferon gamma), and one (Tumor necro-
sis factor alpha induced protein 6) genes after one, three
and seven days of treatment, respectively. Most of the
genes with altered expression were found to be involved
with signal transduction, inflammation and cell survival.
Treatment with imipramine resulted in significant up-
regulation of three (Glial cell line derived neurotrophic
factor superfamily receptor alpha 2, Macrophage
expressed gene 1, Tumor necrosis factor member 11),
13 (Nerve growth factor beta, tumor necrosis factor
receptor regulator, Jun D proto-oncogene, Adenosine
A1 receptor, Neurotrophic tyrosine kinase receptor type
2, Somatostatin receptor 5, Leptin receptor, Arrestin
beta 1, Epsin 1, Caspase 8, Cyclin-dependent kinase 5,
Synuclein alpha, Amyloid beta precursor protein), and
five (Transforming growth factor beta 2, RAB6A mem-
ber RAS oncogene family, Regucalcin, Syntaxin 11,
Homogentisate 1, 2-dioxygenase) genes and down-regu-
lation of five (Leukocyte cell derived chemotaxin 1,
Phospholipase A2 activating protein, Mitogen-activated
protein kinase), one (Interferon gamma), and two
(Tumor necrosis factor alpha induced protein 6, Gran-
zyme A) genes after one, three and seven days of treat-
ment, respectively. Treatment with fluoxetine resulted in
up-regulation of five (Glial cell line derived neurotrophic
factor superfamily receptor alpha 2, Macrophage
expressed gene 1, Tumor necrosis factor member 11,
Activity-dependent neuroprotective protein, Fyn proto-
oncogene), 15 (Nerve growth factor beta, Midkine, Type
1 tumor necrosis factor receptor regulator, Jun D proto-
oncogene, Adenosine A1 receptor, Neurotrophic tyro-
sine kinase, receptor type 2, Somatostatin receptor 5,
Lee et al. BMC Neuroscience 2010, 11:152
http://www.biomedcentral.com/1471-2202/11/152
Page 2 of 10Leptin receptor, Adrenomedullin, Arrestin beta 1,
Epsin 1, Caspase 8, Cyclin-dependent kinase 5, Synu-
clein alpha, Amyloid beta precursor protein) and four
(Transforming growth factor beta 2, Growth differentia-
tion factor 15, RAB6A, Syntaxin 11) genes and down-
regulation of three (Immunoglobulin superfamily
member 6, Secreted phosphoprotein 1, Tumor necrosis
factor receptor superfamily member 6), four (Serum
amyloid A 4, Angiopoietin 1, Apoptosis facilitator Bcl-2-
like protein 14, Interferon gamma) and two (Tumor
necrosis factor alpha induced protein 6, Granzyme A )
genes after 1, 3, and 7 days, respectively. Finally, treat-
ment with phenelzine resulted in up-regulation of three
(Glial cell line derived neurotrophic factor superfamily
receptor alpha 2, Macrophage expressed gene 1, Fyn
proto-oncogene), 14 (Nerve growth factor beta, Midkine,
Type 1 tumor necrosis factor receptor regulator, Jun D
proto-oncogene, Adenosine A1 receptor, Leptin recep-
tor, Adrenomedullin, Arrestin beta 1, Syntaxin 1A,
Epsin 1, Caspase 8, Cyclin-dependent kinase 5, Synu-
clein alpha, Amyloid beta precursor protein), and five
(Transforming growth factor beta 2, Growth differentia-
tion factor 15, Regucalcin, Syntaxin 11, Homogentisate
1, 2-dioxygenase) genes and down-regulation of four
(Immunoglobulin superfamily member 6, Secreted phos-
phoprotein 1, Phospholipase A2 activating protein,
Tumor necrosis factor receptor superfamily member 6),
three (Serum amyloid A 4, Apoptosis facilitator Bcl-2-
like protein 14, Interferon gamma), and two (Tumor
necrosis factor alpha induced protein 6, Granzyme A)
genes after treatment for one, three and seven days,
respectively (Table 1 and 2). Taken together, these data
demonstrate that antidepressants interfere with the
expression of a large array of genes involved in tran-
scription, signaling, survival and protein metabolism
(Figure 2).
Confirmation of the expression of target genes by real
time polymerase chain reaction (RT-PCR)
To confirm the differential expression of genes identified
by microarray analysis, we analyzed the amount of mRNA
that was isolated from the hippocampus of rats that had
been treated with antidepressants by real-time RT-PCR
using primers specific for selected genes of interest. All of
the drugs evaluated in this study induced the up regulation
of factors related to cell survival and inflammation, such as
GFRa2, TNFSF11, Neff, TGFb2a n dG D F 1 5 .H o w e v e r ,
factors related to neurodegeneration and apoptosis were
Figure 1 DNA microarray analysis of RNA isolated from the hippocampus of antidepressant treated rats. A hierarchical clustergram of
genes in treated rat hippocampus was obtained from the control and experimental (antidepressnats) group. Specific pathogen-free, 6 week old
male SD rats were divided into four groups that were subjected to the following treatments: fluoxetine, imipramine, phenelzine and Nelumbinis
Semen. Each group was further subdivided into 3 subgroups (n = 3 per subgroup) that were treated for 1, 3 and 7 days. Fluoxetin (10 mg/kg),
imipramine (10 mg/kg) and phenelzine (5 mg/kg) were administrated intraperitoneally, while Nelumbinis Semen (400 mg/kg) was administered
orally. The control (Con) group was treated with orally administered saline.
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mine, fluoxetine, and phenelzine. Furthermore, factors
related to neurodegenerative diseases, such as CASP8,
APP, and SPP1, were not observed in samples obtained
from the Nelumbinis Semen treated group (Figure 3). Sta-
tistical analysis of the data was conducted using the Prism
3.02 software (GraphicPad Software Inc). Error bars repre-
sent the mean ± SEM for three samples. * p < 0.05, ** p <
0.01 compared with control according to ANOVA and
Newman-keuls analyses.
Discussion
In this study, changes in gene regulation profiles in the
hippocampus of rats in response to treatment with four
different antidepressants, a tricyclic antidepressant (imi-
pramine), a selective serotonin reuptake inhibitor (fluox-
etine), a monoamine oxidase inhibitor (phenelzine) and
a standardized herbal medicine (Nelumbinis Semen),
were evaluated by microarray analysis.
Many previous studies of antidepressants have focused
on the cAMP cascade and alterations in the synaptic
levels of monoamines [12,13]. However, major depres-
sion is accompanied by activation of the inflammatory
response system, and antidepressants may have immu-
noregulatory activity. Antidepressants have also been
found to exert immunoregulatory effects on human leu-
kocyte functions, especially cytokine production.
Furthermore, tricyclic antidepressants and heterocyclic
antidepressants can have negative immunoregulatory
effects because they inhibit stimulatory cytokines while
enhancing inhibitory cytokine production [14,15].
This neuroinflamation and apoptosis includes regulation
of intracellular signal transduction pathways and gene
expression. Indeed, in this study, treatment with antide-
pressants was found to primarily be involved with altera-
tions in the expression of several genes related to
neuroinflamation and apoptosis. Moreover, the antidepres-
sants evaluated in this study lead to the over-expression of
Table 1 List of significantly over-expressed genes affected by antidepressants
Clone name (mRNA) Fold change (log2 mean) Accession number
NS Imip Fluo Phen
Transforming growth factor, beta 2 1.6 (7) 1.8 (7) 2.0 (7) 2.3 (7) NM_031131
Growth differentiation factor 15 1.3 (7) 1.0 (7) 1.4 (7) NM_019216
Nerve growth factor, beta 1.0 (3) 1.7 (3) 1.4 (3) 1.7 (3) XM_001067130
Glial cell line derived neurotrophic factor superfamily receptor alpha 2 1.1 (1) 1.1 (1) 1.0 1.1 (1) NM_012750
Macrophage expressed gene 1 1.7 (1) 1.4 (1) 1.5 (1) 1.1 (1) NM_022617
Midkine 1.2 (3) 1.4 (3) NM_030859
Tumor necrosis factor, member 11 1.4 (1) 1.3 (1) NM_057149
Type 1 tumor necrosis factor receptor regulator 2.0 (3) 1.7 (3) 1.4 (3) 2.2 (3) NM_030836
Activity-dependent neuroprotective protein 1.0 (1) 1.3 (1) NM_012755
Fyn proto-oncogene 1.1 (1) 1.3 (1) 1.1 (1) NM_012755
Jun D proto-oncogene 2.0 (3) 1.7 (3) 1.9 (3) NM_138875
RAB6A, member RAS oncogene family 1.1 (7) 1.0 (7) XM_001062702
Adenosine A1 receptor 1.0 (3) 1.0 (3) 1.0 (3) NM_017155
Neurotrophic tyrosine kinase, receptor, type 2 1.0 (3) 1.0 (3) NM_012731
Somatostatin receptor 5 1.5 (3) 1.8 (3) NM_012882
Leptin receptor 1.1 (3) 1.2 (3) 1.1 (3) 1.5 (3) NM_012596
Adrenomedullin 1.2 (3) 1.2 (3) 1.1 (3) NM_012715
Adrenomedullin receptor 1.2 (7) XM_001076934
Arrestin, beta 1 1.0 (3) 1.5 (3) 1.3 (3) NM_012910
Regucalcin 1.3 (7) 1.2 (7) 1.9 (7) NM_031546
Syntaxin 1A (brain) 1.5 (3) 1.3 (3) NM_053788
Syntaxin 11 1.7 (7) 1.6 (7) 1.7 (7) 2.1 (7) NM_001025638
Epsin 1 1.2 (3) 1.5 (3) 1.6 (3) 1.4 (3) NM_057136
Caspase 8 1.5 (3) 1.8 (3) 1.0 (3) NM_022277
Cyclin-dependent kinase 5 (p35) 1.1 (3) 1.2 (3) 1.1 (3) NM_053891
Synuclein, alpha 1.0 (3) 1.4 (3) 1.4 (3) NM_019169
Amyloid beta (A4) precursor protein 1.0 (3) 1.1 (3) 1.3 (3) NM_019288
Homogentisate 1, 2-dioxygenase 2.4 (7) 2.3 (7) NM_001012145
List of over-expressed genes affected more than 2 fold to their specific control by antidepressant treatments. ( ) indicated the sacrificed day of oral administered
rat with antidepressant. NS; Nelumbinis Semen, Imip; imipramine, Fluo; fluoxetine, Phen; phenelzine
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ture, survival, nuclear function and metabolism. Finally,
we found that acute administration of antidepressants had
an impact on cell cycle and survival, and that chronic
treatment resulted in the regulation of factors involved in
neuroinflamation and apoptosis. However, the specific
gene expression patterns depending on the duration of
treatment were not clearly identified in the present study.
The role of imipramine in gene expression
Treatment with the tricyclic antidepressant, imipra-
mine, resulted in the up regulation of 35 genes and the
down regulation of 21 genes involved in signal trans-
duction, metabolism, inflammation, transport, apopto-
sis, and biological process in general (Table 1 and 2).
The DEGs related to cell regulation included TGFb2
(transforming growth factor, beta 2), NGFb (nerve
growth factor, beta), TNF11 (tumor necrosis factor 11),
and RANKL (Receptor Activator for Nuclear Factor
 B Ligand).
Transforming growth factor-beta 2 (TGF-b2) is a cyto-
kine that is known to perform many cellular functions
and to play a vital role in embryonic development. TGF-
b2i sa l s ok n o w nt os u p p r e s st h ee f f e c t so fi n t e r l e u k i n
dependent T-cell tumors. RANKL is known as a TNF-
related activation-induced cytokine. Overproduction of
RANKL is implicated in a variety of degenerative bone
diseases, including rheumatism [16]. In addition,
R A N K Li sk n o w nt op l a yar o l ei nt h ei m m u n es y s t e m ,
w h e r ei ti se x p r e s s e db yTh e l p e rc e l l sa n db e l i e v e dt o
be involved in cell maturation. Furthermore, RANKL
has been shown to be a cell survival factor that is
involved in the regulation of T cell-dependent immune
response [17].
The role of fluoxetine in gene expression
Treatment with the selective serotonin reuptake inhibi-
tor, fluoxetine, resulted in the over-expression of 49
g e n e sa n dt h er e p r e s s i o no f2 0g e n e s( T a b l e1a n d2 ) ;
however, the genes affected by fluoxetine varied widely.
The affected genes included TGFb2, JunD (Jun D proto-
oncogene) and Adenosine A1 receptor, which were
up-regulated, and GZMA (Granzyme A) and IFNg
(interferon gamma), which were down-regulated.
It has been proposed that Jun D proto-oncogene pro-
tects cells from p53-dependent senescence and apopto-
sis. The adenosine A1 receptor is a member of the
adenosine receptor group of G protein-coupled recep-
tors that use adenosine as an endogenous ligand. These
receptors are believed to take part in the promotion of
sleep by inhibiting wake promoting cholinergic neurons
in the basal forebrain [18,19]. Granzymes are exogenous
serine proteases that are released by cytoplasmic gran-
ules within cytotoxic T cells and natural killer cells.
Their purpose is to induce apoptosis within virus-
infected cells, thereby destroying them [20,21].
The role of phenelzine in gene expression
Treatment with the monoamine oxidase inhibitor, phe-
nelzine, resulted in increased expression of 35 genes and
down-regulation of 37 genes (Table 1 and 2). The genes
affected by treatment with phenelzine were involved in
various process, and included TGFb2, GDF15 (growth
differentiation factor 15), and LepR (leptin receptor),
which were over expressed, and SPP1 (secreted phos-
phoprotein 1), which was down-regulated.
Growth differentiation factor 15 (GDF15) is a protein
that belongs to the transforming growth factor beta
superfamily and plays a role in the regulation of
Table 2 List of significantly repressed genes affected by antidepressants
Clone name (mRNA) Fold change (log2 mean) Accession number
NS Imip Fluo Phen
Immunoglobulin superfamily, member 6 -2.4 (1) -2.2 (1) -1.5 (1) NM_133542
Secreted phosphoprotein 1 -2.3 (1) -2.5 (1) -2.2 (1) NM_012881
Tumor necrosis factor alpha induced protein 6 -1.5 (7) -1.6 (7) -1.2 (7) -1.0 (7) XM_001065494
Leukocyte cell derived chemotaxin 1 -1.8 (1) -1.3 (1) NM_030854
Phospholipase A2, activating protein -2.5 (1) -1.6 (1) NM_053866
Serum amyloid A 4 -1.5 (3) -1.4 (3) -1.3 (3) NM_001009478
Mitogen-activated protein kinase 4 -1.1 (1) XM_001053505
Tumor necrosis factor receptor superfamily, member 6 -1.8 (1) -1.1 (1) NM_139194
Angiopoietin 1 -3.8 (3) -3.1 (3) NM_053546
Apoptosis facilitator Bcl-2-like protein 14 -2.5 (3) -1.0 (3) -1.0 (3) NM_001024338
Interferon gamma -2.4 (3) -1.0 (3) NM_138880
Granzyme A -2.0 (7) -2.0 (7) -1.2 (7) NM_153468
List of repressed genes affected less than 2 fold to their specific control by antidepressant treatments. ( ) indicated the sacrificed day of oral administered rat
with antidepressant. NS; Nelumbinis Semen, Imip; imipramine, Fluo; fluoxetine, Phen; phenelzine
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Page 5 of 10inflammatory and apoptotic pathways activated in
response to tissue injury and during disease processes.
Furthermore, the expression of GDF15 in liver can be
significantly up-regulated in response to injury of the
liver, brain, kidney, heart and lung [22,23]. Leptin,
which is produced by adipose tissue, plays a key role in
the regulation of energy intake and expenditure, includ-
ing the regulation of appetite. Specifically, leptin binds
to the ventromedial nucleus of the hypothalamus, which
sends a signal to the brain indicating that the body has
had enough to eat [24]. Secreted phosphoprotein 1
(SSP1) is an extracellular structural protein and an
organic component of bone. High levels of SSP1 expres-
sion are correlated with tumor invasion, progression or
metastasis in multiple forms of cancer. SSP1 mediates
the molecular mechanisms that determine metastatic
spread, such as the prevention of apoptosis, extracellular
matrix proteolysis, remodeling and cell migration [25].
The role of Nelumbinis Semen in gene expression
Nelumbinis Semen has been widely used in traditional
medicine as a remedy for insomnia, anxiety and
women’s depression following menopause. In previous
reports, we found that this herbal medicine produced an
antidepressant effect on rats under a forced swim-
induced depression-like symptom [11], as well as a
chronic mild stress (CMS)-induced depression-like
symptom [10]. We also recently conducted a study that
Figure 2 The functional categories of DEGs identified by DNA microarray analysis of isolated RNA from the rat hippocampus of rats
that were treated with antidepressants. The functional categories of up-regulated genes are shown.
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levels, which are normally decreased in depression,
thereby enhancing central serotonergic transmission and
possibly providing therapeutic action for the treatment
of depression. This is similar to the results of other stu-
dies that have suggested that Nelumbinis Semen induces
an antidepressant effect through the enhancement of
serotonin [9].
Treatment with Nelumbinis Semen resulted in
increased expression of 44 genes and decreased expres-
sion of 27 genes (Table 1 and 2). The genes affected by
Nelumbinis Semen were involved in various fields and
included TGFb2 and GFRa2 (glial cell line derived neu-
rotrophic factor family receptor alpha 2), which were
up-regulated, as well as IFNg, which was downregulated.
Glial cell derived neurotrophic factor, also known as
GDNF, is a small protein that promotes the survival of a
wide variety of neurons [26]. This gene encodes a highly
conserved neurotrophic factor. In addition, the recombi-
nant form of this protein is known to promote the sur-
vival and differentiation of dopaminergic neurons in
culture, and to prevent axotomy induced apoptosis in
motor neurons [27,28]. IFNg (also known as immune
interferon) is a dimerized soluble cytokine that is the
only member of the type II class of interferons and is
secreted by T lymphocytes [29]. IFN-g has antiviral,
immunoregulatory, and anti-tumor properties [30].
The molecular and biological mechanisms by which
antidepressant action occurs are not fully understood,
and various explanations of the expression profiles gen-
erated in many similar studies have been offered. In this
study, we found that DNA microarrays provided an effi-
cient tool for evaluating changes in gene expression in
response to treatment with antidepressants. The use of
this method allowed us to isolate several mRNAs from
the rat hippocampus that were differentially expressed
in response to treatment with antidepressants. Some of
these genes have been identified in previous studies and
others are candidates for further study. In the present
study, administration of three antidepressants and a tra-
ditional herbal medicine was found to affect a wide
range of genes involved in various processes. For exam-
ple, all four drugs induced the up regulation of factors
related to cell survival such as TGFb,N G F b,G F R a2,
and TNF. These results suggest that antidepressants reg-
ulate the cAMP cascade and alterations in synaptic
levels of monoamines, as well as cell survival and neu-
roinflamation. However, some factors associated with
neurodegenerative diseases were up-regulated in
response to treatment with the three antidepressants
evaluated in this study (imipramine, fluoxetine, and phe-
nelzine) (Table 1 and 2). These factors included caspase
8, a-synuclein, amyloid b precursor protein and cyclin-
dependent kinase. Caspase 8 plays a central role in the
execution-phase of cell apoptosis. Synuclein selectively
inhibits phospholipase D2 and is abundant in neurofi-
brillary lesions of patients with Alzheimer’s disease [31].
Dysregulation of cyclin-dependent kinase 5 (CDK5) has
been implicated in several neurodegenerative diseases,
including Alzheimer’s [32,33]. Taken together, these
results show that the three commonly used medications
evaluated in this study have the potential to produce
adverse effects. However, Nelumbinis Semen did not up-
regulate any factors related to neurodegenerative
diseases.
Major depression is associated with an increased
secretion of IFNg. Moreover, the administration of IFNg
results in behavioral effects and depression-like syn-
dromes [34,35]. Antidepressants have been found to sig-
nificantly enhance the production of another inhibitory
cytokine, TGFg. This cytokine is known to inhibit sev-
eral immune reactions, including autoimmune disorders
[14]. Interestingly, we found a general trend in which
production of the stimulatory cytokine, IFNg,w a s
decreased in response to treatment with all of the
Figure 3 Quantitative determination of mRNA levels in rat
hippocampus obtained from rats that were administered
antidepressants as determined by RT-PCR. Changes in the mRNA
levels of DEGs identified in rat hippocampus from rats that had
been treated with antidepressants were confirmed by real time PCR.
Ten DEGs identified by microarray analysis were selected for
confirmation. The dashed line indicates the control mRNA levels. All
data were normalized by dividing the results by the amount of
GAPDH expressed. Data are presented as mean ± S.E.M. (n = 4) *p
< 0.05 and ** p < 0.01 compared to control.
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of the inhibitory cytokine, TGFg, was significantly
enhanced by treatment with the antidepressants evalu-
ated here.
Many previous studies have reported that antidepres-
sant-induced alterations in mRNA expression are
involved in stress and survival, the cell cycle, neuro-
transmission, and metabolism in general [36-38]. When
combined with our findings, these observations suggest
that antidepressants with different molecular structures
share similar targets at the molecular level.
Conclusion
Our results demonstrate that antidepressants interfere
with the expression of a large array of genes involved in
various processes, suggesting that the therapeutic effect
of these antidepressants is very complex. Unlike other
antidepressants, we found that the standardized herbal
medicine, Nelumbinis Semen, is free of factors that can
induce neurodegenerative diseases.
Methods
Animal and drug treatment
This study was conducted using specific pathogen-free,
six week old male Sprague-Dawley (SD) rats (Charles
River Technology Inc. Korea). The SD rats were
housed in a controlled environment (12:12-hour light:
dark cycle, temperature 23 ± 2°C, humidity 50 ± 10%)
with water and food available ad libitum.T h er a t s
were divided into four groups that were subjected to
the following treatments: fluoxetin, imipramine, phe-
nelzine and Nelumbinis Semen. The three antidepres-
sants were dissolved in saline while the Nelumbinis
Semen was dissolved in distilled water. Each group was
further subdivided into three subgroups (n = 3 per
subgroup) that were treated for 1, 3 and 7 days with
one of the four drugs. Fluoxetin (10 mg/kg), imipra-
mine (10 mg/kg) and phenelzine (5 mg/kg) were admi-
nistrated intraperitoneally, while Nelumbinis Semen
(400 mg/kg) was administered orally by intubation
using a stainless steel ball-tipped gavage needle
attached to an appropriate syringe. The day after treat-
ment, the rats were sacrificed and their hippocampuses
were collected by dissection from removed each hemi-
sphere. The samples were then immediately frozen
with liquid nitrogen and stored at -80°C until RNA
isolation. There was also a control group of rats that
were only treated with saline. Fluoxetin, imipramine
and phenelzine were obtained from Sigma (St. Louis,
MO, USA), and Nelumbinis Semen was purchased
from Sun Ten Pharmaceutical (Taipei, Taiwan). The
experiments began when the rats were six weeks old,
and all of the procedures involving animals were
approved by the Institutional Animal Care and Use
Committee of Kyung Hee University.
RNA preparation
RNA was extracted from the rat hippocampus using an
Rneasy® mini kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s instructions. The
extracted RNA was then quantified using NanoDrop
(NanoDrop Technologies, Inc ND-1000; Wilmington,
DE, U.S.A).
Oligonucleotide chip microarray
An oligonucleotide chip microarray was performed
using single round RNA amplification protocols, follow-
ing the Affimetrix specifications (Affimetrix GeneChip
Expression Analysis Technical Manual). Briefly, 3 micro-
grams of total RNA were used to synthesize first-strand
complementary DNA (cDNA) using oligonucleotide
probes with 24 oligo-dT plus T7 promoter as primers
(Proligo LLC, Boulder, CO, USA) and the Superscript
Choice System (Life Technologies, Invitrogen, Milan,
Italy). After double-stranded cDNA synthesis, the pro-
ducts were purified by phenol-chloroform extraction,
and then biotinylated antisense complimentary RNA
(cRNA) was generated through in vitro transcription
using a Genechip Expression 3’-Ampliflcation Reagent
for IVT Labeling kit (Affymetrix, Inc. USA). Next, the
biotinylated labeled cRNA was fragmented, and 10 μgo f
the total fragmented cRNA was then hybridized to the
Affymetrix Rat 230 2.0 GeneChip array (P/N900470,
Affymetrix Inc., USA). The Affimetrix Fluidics Station
450 was then used to wash and stain the chips, after
which the nonhybridized target was removed. Next, the
samples were incubated with a streptavidin-phycoery-
thrin conjugate to stain the biotinylated cRNA. The
staining was then amplified using goat IgG as a blocking
reagent and biotinylated antistreptavidin antibody (goat),
followed by a second staining step using a streptavidin-
phycoerythrin conjugate. The fluorescence was detected
using the Genechip System Confocal Scanner (Hewlett-
Packard), and analysis of the data contained on each
GeneChip was conducted using the GeneChip 3.1 soft-
ware produced by Affymetrix, using the standard default
settings. To compare different chips, global scaling was
used, with all probe sets being scaled to a user-defined
target intensity of 150. Total of 45 rats (5 group × 3
subgroup × 3 individual) were separately performed
microarray analysis.
Data analysis
The MAS5 algorithm was used to evaluate the expres-
sion signals generated by the Affymetrix Rat 230 2.0
array. Global scaling normalization was then performed,
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using base 2. Next, fold change and a Welch t-test were
used to select the differentially expressed genes (DEGs)
using a fold change threshold of 2.0-fold and a P < 0.05
to indicate significance. Each probe set used in the Affy-
metrix GeneChip produces a detection call, with P (pre-
sent call) indicating good quality, M (marginal call)
indicating intermediate quality and A (absent call) indi-
cating relatively low reliability. Therefore, probe sets
that resulted in A calls in the compared groups were
removed to avoid false positives. A volcano plot was
used to better visualize and compare the two DEG
methods. The 2.0-fold DEGs were clustered using the
GenPlex™ v2.3 software (ISTECH Inc., Korea) using
hierarchical clustering with Pearson’s correlation as a
similarity measure and complete linkage as the linkage
method. In addition, gene ontology significance analysis
was conducted to evaluate the functional relationships
among the 2.0-fold DEGs using high-throughput GoMi-
ner. The 2.0-fold DEGs were then mapped to the rele-
vant pathways using the GenPlex™ v2.4 software
(ISTECH Inc., Korea). The pathway resources were pro-
vided by the KEGG database.
Real-time RT-PCR analysis
Microarray verification was performed by real-time RT-
PCR analysis of selected genes using SYBR Green I Mas-
ter Mix (Applied Biosystems, Foster City, CA, U.S.A)
and primers (Genotech Inc. Korea). Complementary
DNA (cDNA) was synthesized using 1 μgo ft o t a lR N A
in a reverse transcription reaction. Real time-PCR quan-
titative mRNA analyses were performed with an Applied
Biosystems 7300 Real Time PCR System using the SYBR
Green fluorescence quantification system (Applied Bio-
systems, Foster City, CA, U.S.A) to quantify the ampli-
cons. The PCR conditions were 40 cycles of 95°C
(15 sec), 60°C (1 min), and a standard denaturation
curve. PCR conditions for each target were optimized
according to the primer concentration, the absence of
primer dimmer formation, and the efficiency of amplifi-
cation of both the target genes and the housekeeping
gene control. PCR reactions were carried out in a total
volume of 20 μL in PCR master mix containing 10 μL
2X SYBR Green, 5 μM each of sense and antisense pri-
mer, and 2 μL of 1:2 diluted cDNA filled up to 20 μL
with DEPC-treated H2O. To normalize the cDNA con-
tent of the samples, we used the comparative threshold
(CT) cycle method, which consists of the normalization
of the number of target gene copies versus the endogen-
ous reference gene, GAPDH. The CT is defined as the
fractional cycle number at which the fluorescence gener-
ated by cleavage of the probe passes a fixed threshold
baseline when amplification of the PCR product is first
detected.
Statistical analysis of the data was carried out using
the Prism 3.02 software (GraphicPad Software Inc).
Error bars represent the mean ± SEM for three samples.
* p < 0.05, ** p < 0.01 compared with control according
to ANOVA and Newman-keuls analyses.
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